Table 3.
Predictors of DTG discontinuation for any reason and for toxicity by multivariable Cox regression models according to treatment group (A: ART‐naïve group and B: TE group)
| (A) ART‐naïve group Variables | Discontinuation for any reason | Discontinuation for toxicity | ||
|---|---|---|---|---|
| aRHa (95% CI) | p‐Value | aRHa (95% CI) | p‐Value | |
| Gender | ||||
| Female | 1.46 (0.67 to 3.19) | 0.340 | 1.48 (0.45 to 4.84) | 0.515 |
| Age, years | ||||
| Per 10 older | 1.15 (0.94 to 1.40) | 0.181 | 1.26 (0.88 to 1.79) | 0.208 |
| AIDS diagnosis | ||||
| Yes vs. no | 3.38 (1.62 to 7.05) | 0.001 | 2.82 (0.96 to 8.28) | 0.060 |
| Calendar year of baseline | ||||
| Per more recent year | 1.26 (0.81 to 1.95) | 0.313 | 1.37 (0.74 to 2.52) | 0.318 |
| Baseline CD4 count, cells/mmc | ||||
| Per 100 higher | 0.98 (0.86 to 1.11) | 0.730 | 0.96 (0.81 to 1.13) | 0.601 |
| HIV‐RNA, log10 copies/mL | ||||
| Per log higher | 1.27 (0.87 to 1.84) | 0.216 | 1.13 (0.69 to 1.87) | 0.623 |
| NRTI backbone | ||||
| TDF or TAF/FTC | 1.00 | 1.00 | ||
| 3TC/ABC | 1.39 (0.79 to 2.46) | 0.253 | 3.30 (1.34 to 8.11) | 0.009 |
| (B) TE group Variables | Discontinuation for any reason | Discontinuation for toxicity | ||
|---|---|---|---|---|
| aRHb (95% CI) | p‐Value | aRHb (95% CI) | p‐Value | |
| Gender | ||||
| Female | 1.11 (0.52 to 2.33) | 0.799 | 1.78 (0.66 to 4.78) | 0.255 |
| Age, years | ||||
| Per 10 older | 1.07 (0.81 to 1.41) | 0.639 | 0.97 (0.66 to 1.42) | 0.869 |
| AIDS diagnosis | ||||
| Yes vs. no | 1.32 (0.64 to 2.72) | 0.450 | 1.35 (0.50 to 3.68) | 0.552 |
| Calendar year of baseline | ||||
| Per more recent year | 1.06 (0.60 to 1.88) | 0.839 | 0.89 (0.43 to 1.87) | 0.767 |
| DTG‐regimenc | ||||
| Dual | 1.00 | 1.00 | ||
| Triple with ABC | 2.50 (1.06 to 5.93) | 0.037 | 5.26 (1.17 to 23.56) | 0.030 |
| Triple with TDF/TAF | 3.56 (1.33 to 9.53) | 0.012 | 6.60 (1.29 to 33.85) | 0.024 |
| Duration of VS | ||||
| Per six months longer | 0.94 (0.88 to 0.99) | 0.028 | 0.94 (0.83 to 1.07) | 0.352 |
ART, antiretroviral therapy; TE, treatment‐experienced; aRH, adjusted relative hazard; CI, confidence intervals; NRTI, nucleoside reverse transcriptase inhibitor; FTC, emtricitabine; 3TC, lamivudine; DTG, dolutegravir; ABC, abacavir; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide fumarate; VS, viral suppression. Bold values represent statistically significant p‐values.
aAfter adjusting mode of HIV transmission, nationality, hepatitis coinfection; bafter adjusting for mode of HIV transmission, nationality, hepatitis co‐infection, baseline CD4 cell count, reasons for stopping previous regimen, previous virological failure, duration of ART; cother therapies group not shown because no events occurred.